Full Text View
Tabular View
No Study Results Posted
Related Studies
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), August 2007
First Received: October 3, 2003   Last Updated: May 9, 2009   History of Changes
Sponsors and Collaborators: University of Leeds
Medical Research Council
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00070213
  Purpose

RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, capecitabine, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether leucovorin and fluorouracil with or without oxaliplatin is more effective than capecitabine with or without oxaliplatin in treating patients who have metastatic colorectal cancer.

PURPOSE: This randomized phase III trial is studying four different chemotherapy regimens to compare how well they work in treating patients with metastatic colorectal cancer.


Condition Intervention Phase
Colorectal Cancer
Quality of Life
 Drug: FOLFOX regimen
Drug: capecitabine
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: quality-of-life assessment
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Official Title: Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed

Resource links provided by NLM:

MedlinePlus related topics: Calcium Cancer Colorectal Cancer
Drug Information available for: Fluorouracil Leucovorin Citrovorum factor Oxaliplatin Capecitabine Leucovorin Calcium Folinic acid calcium salt pentahydrate
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Compare progression-free survival (PFS) in pts. treated w/ leucovorin calcium + fluorouracil (MdG) vs leucovorin calcium + fluorouracil + oxaliplatin (OxMdG) and in pts. treated w/ capecitabine (Cap) vs capecitabine + oxaliplatin (OxCap) at 1 yr [ Designated as safety issue: No ]
  • Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare health assessment, including quality of life, in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap at baseline and 14 and 24 weeks [ Designated as safety issue: No ]
  • Compare toxicity/adverse events in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap [ Designated as safety issue: Yes ]
  • Compare overall failure-free survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap [ Designated as safety issue: No ]
  • Compare overall survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap [ Designated as safety issue: No ]
  • Compare health economics in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap [ Designated as safety issue: No ]
  • Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap [ Designated as safety issue: No ]
  • Compare toxicity/adverse events in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 24 weeks [ Designated as safety issue: Yes ]
  • Compare patients acceptability in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap [ Designated as safety issue: No ]
  • Compare PFS in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap [ Designated as safety issue: No ]
  • Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap [ Designated as safety issue: No ]

Estimated Enrollment: 460
Study Start Date: September 2003
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of colorectal adenocarcinoma, defined by 1 of the following:

    • Prior or current histologically confirmed primary adenocarcinoma of the colon or rectum with clinical/radiological evidence of advanced/metastatic disease
    • Histologically or cytologically confirmed metastatic adenocarcinoma with clinical/radiological evidence of colorectal primary tumor
  • Unidimensionally measurable disease

  • Unfit and unsuitable for full-dose combination chemotherapy, which would include 1 of the following circumstances:

    • Unsuitable or unwilling to be entered into any full-dose chemotherapy protocol
    • Ineligible or unsuitable for first-line standard combination as per National Institute of Clinical Excellence guidance

PATIENT CHARACTERISTICS:

Age

  • Not specified

Performance status

  • WHO 0-2

Life expectancy

  • Not specified

Hematopoietic

  • WBC greater than 3,000/mm^3
  • Platelet count greater than 100,000/mm^3

Hepatic

  • Bilirubin no greater than 3 times upper limit of normal (ULN)
  • AST or ALT no greater than 2.5 times ULN

Renal

  • Creatinine clearance greater than 50 mL/min OR
  • Glomerular filtration rate greater than 30 mL/min

Cardiovascular

  • No uncontrolled angina
  • No recent myocardial infarction

Other

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No partial or complete bowel obstruction
  • No concurrent severe uncontrolled medical illness that would preclude study treatment
  • No psychiatric or neurological condition that would preclude giving informed consent or complying with oral study medication
  • No other prior or concurrent malignant disease that would preclude study treatment or assessment of response
  • No prior neuropathy greater than grade 1

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • More than 4 months since prior adjuvant chemotherapy with fluorouracil with or without leucovorin calcium
  • More than 1 month since prior rectal chemoradiotherapy with fluorouracil with or without leucovorin calcium
  • No prior systemic palliative chemotherapy for metastatic disease

Endocrine therapy

  • Not specified

Radiotherapy

  • See Chemotherapy

Surgery

  • Not specified

Other

  • No concurrent brivudine or sorivudine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00070213

Locations
United Kingdom, England
Clinical Trials and Research Unit of the University of Leeds Recruiting
Leeds, England, United Kingdom, LS2 9JT
Contact: Phil Quirke     44-113-233-3412        
Cookridge Hospital Recruiting
Leeds, England, United Kingdom, LS16 6QB
Contact: Matthew T. Seymour, MA, MD, FRCP     44-113-267-3411        
Medical Research Council Clinical Trials Unit Recruiting
London, England, United Kingdom, NW1 2DA
Contact: Gareth Griffiths     44-20-7670-4704        
United Kingdom, Wales
Velindre Cancer Center at Velindre Hospital Recruiting
Cardiff, Wales, United Kingdom, CF14 2TL
Contact: Alison Brewster, MD     44-29-2031-6220        
Sponsors and Collaborators
University of Leeds
Medical Research Council
Investigators
Investigator: Matthew T. Seymour, MA, MD, FRCP Cookridge Hospital
Investigator: Gareth Griffiths Medical Research Council
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:
Seymour MT, Maughan TS, Wasan HS, et al.: Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-9030, 500s, 2007.

Study ID Numbers: CDR0000330142, NCRI-FOCUS2, MRC-CR09, EU-20303
Study First Received: October 3, 2003
Last Updated: May 9, 2009
ClinicalTrials.gov Identifier: NCT00070213     History of Changes
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
quality of life
adenocarcinoma of the colon
adenocarcinoma of the rectum
stage IV rectal cancer
 stage IV colon cancer
recurrent rectal cancer
recurrent colon cancer

Study placed in the following topic categories:
Antimetabolites
Immunologic Factors
Gastrointestinal Diseases
Rectal Neoplasms
Colonic Diseases
Quality of Life
Leucovorin
Rectal Diseases
Oxaliplatin
Vitamins
Micronutrients
Capecitabine
Digestive System Neoplasms
Vitamin B Complex
 Rectal Neoplasm
Trace Elements
Folinic Acid
Intestinal Diseases
Immunosuppressive Agents
Intestinal Neoplasms
Recurrence
Calcium, Dietary
Rectal Cancer
Digestive System Diseases
Fluorouracil
Gastrointestinal Neoplasms
Adenocarcinoma
Colorectal Neoplasms

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Gastrointestinal Diseases
Antineoplastic Agents
Colonic Diseases
Physiological Effects of Drugs
Leucovorin
Rectal Diseases
Oxaliplatin
Neoplasms by Site
Vitamins
Therapeutic Uses
 Micronutrients
Capecitabine
Digestive System Neoplasms
Vitamin B Complex
Growth Substances
Intestinal Diseases
Immunosuppressive Agents
Intestinal Neoplasms
Pharmacologic Actions
Neoplasms
Digestive System Diseases
Fluorouracil
Gastrointestinal Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services